Global Preventable Vaccines Market Size By Type (Adult Preventable Vaccines, Pediatric Preventable Vaccines), By Application (Bacterial Diseases, Virus Diseases), By Region, And Segment Forecasts, 202...

The Global Preventable Vaccines Market was valued at USD 54.7 billion in 2023 and is projected to reach USD 96.4 billion by 2031, growing at a CAGR of 7.3% during the forecast period from 2023 to 2031. This market is propelled by increasing government immunization initiatives, rising awareness regarding disease prevention, and technological advancements in vaccine development. Preventable vaccines play a vital role in reducing the global burden of infectious diseases such as measles, hepatitis, influenza, HPV, and tuberculosis. With growing demand in both developed and developing regions, the market continues to evolve through innovation and public-private partnerships.

Drivers:

1. Global Immunization Programs:

WHO- and UNICEF-backed vaccination drives and government-led immunization schedules have significantly boosted the uptake of preventable vaccines, especially in low- and middle-income countries.

2. Rising Disease Awareness:

Improved healthcare literacy and public awareness regarding the importance of vaccines for children and adults are increasing vaccine adoption rates globally.

3. Technological Advancements:

Progress in biotechnology, such as mRNA platforms and recombinant DNA technology, has accelerated vaccine production and improved efficacy, safety, and scalability.

Restraints:

1. Vaccine Hesitancy and Misinformation:

Public skepticism, misinformation via social platforms, and anti-vaccination movements remain major barriers to higher immunization coverage in certain regions.

2. Cold Chain and Storage Challenges:

Many vaccines require stringent cold-chain logistics, which remain difficult to maintain in under-resourced regions, limiting distribution and reach.

Opportunity:

1. Expansion in Emerging Markets:

Countries in Africa, Asia-Pacific, and Latin America are increasingly investing in healthcare infrastructure and preventive care, presenting lucrative market opportunities.

2. Innovations in Vaccine Delivery:

Needle-free delivery systems, thermostable vaccines, and single-dose formulations are enhancing convenience, improving access, and reducing costs.

Market by System Type Insights:

Based on vaccine type, the Combination Vaccines segment led the market in 2023. These vaccines offer protection against multiple diseases with a single injection, increasing compliance and reducing administration costs. The Conjugate Vaccines segment is also expected to show robust growth, driven by rising demand for pediatric immunizations against diseases like pneumococcal and meningococcal infections.

Market by End-use Insights:

By end-use, the Pediatric Vaccination segment dominated the market in 2023, accounting for over 60% of the global revenue share. Childhood immunization remains a priority in both national health agendas and global development goals. Meanwhile, the Adult & Geriatric Vaccination segment is gaining momentum, fueled by aging populations and increased focus on diseases like shingles, influenza, and HPV.

Market by Regional Insights:

Geographically, North America held the largest market share in 2023 due to high vaccine coverage, robust healthcare infrastructure, and the presence of leading pharmaceutical companies. However, Asia-Pacific is expected to record the highest CAGR through 2031, supported by expanding immunization programs, growing healthcare investments, and increasing population density in countries like India and China.

Competitive Scenario:

Key players in the Global Preventable Vaccines Market include GlaxoSmithKline plc, Pfizer Inc., Sanofi, Merck & Co., Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, CSL Limited, AstraZeneca plc, and Moderna, Inc. These companies are actively engaged in partnerships with health agencies, continuous innovation, and regional expansions.

Key Market Developments:

2023: Pfizer and BioNTech launched a next-generation mRNA-based influenza vaccine in clinical trials.

2024: Serum Institute of India expanded its manufacturing facilities to support global supply of combination vaccines.

2025: GSK announced a strategic collaboration with African vaccine manufacturers to improve local access and production capabilities.

Scope of Work – Global Preventable Vaccines Market

FAQs:

1) What is the current market size of the Global Preventable Vaccines Market?

The market was valued at USD 54.7 billion in 2023.

2) What is the major growth driver of the Global Preventable Vaccines Market?

The major growth driver is the rise in global immunization programs supported by public health agencies.

3) Which is the largest region during the forecast period in the Global Preventable Vaccines Market?

North America is the largest regional market in 2023, but Asia-Pacific is expected to grow the fastest through 2031.

4) Which segment accounted for the largest market share in the Global Preventable Vaccines Market?

The Pediatric Vaccination segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Preventable Vaccines Market?

Key players include GlaxoSmithKline plc, Pfizer Inc., Sanofi, Merck & Co., Inc., Johnson & Johnson, Serum Institute of India, and Moderna, Inc.